Lonza AG (Basel, Switzerland) announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2,000 m2 with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering, which include drug substance, particle engineering technologies such as spray drying dispersion, and drug product.
This construction project is supported by a capital contribution and a tailored long-term collaboration with a major biopharmaceutical partner to ensure continuity of supply and flexibility, supporting future demand for their product. The first buildout represents a dedicated manufacturing line for antibody-drug conjugate payload molecules, which is expected to start its first operations in Q3 2023. Upon completion, the manufacturing complex will employ approximately 200 people.
By Mary Page Bailey
The total contract value is approximately €430 million. The project scope of work entails complete engineering services, equipment and material supply, installation and construction activities and, as an optional part of the scope, commissioning and start up.
Once it has implemented this project, Lenzing will have biological wastewater treatment plants that meet the best available techniques (BAT) quality standard at all its production sites.
The debate over the position of hydrogen in the new energy revolution has come to the fore again thanks to Japan’s hosting of the Olympic Games. But rather than showcasing how green this miracle new fuel is, it has highlighted its many problems.